Showing 3001-3010 of 5909 results for "".
- FDA Grants Breakthrough Device Designation to Concussion Assessment Devicehttps://modernod.com/news/fda-grants-breakthrough-device-designation-to-concussion-assessment-device/2476351/SyncThink announced that the FDA has granted Breakthrough Device Designation to EYE-SYNC, an objective eye-tracking platform. The EYE-SYNC platform is used to assist clinicians in evaluating visual impairments, monitor recovery, and support the rehabilitation of ocular-motor and ocular-vestibular
- New Data From Alcon Shows that Compliant Contact Lens Wear Can Improve Practice Outcomeshttps://modernod.com/news/new-data-from-alcon-shows-that-compliant-contact-lens-wear-can-improve-practice-outcomes/2479590/Alcon unveiled new data from its Power of One 2.0 Program showing how patient compliance with daily and monthly contact lens replacement schedules can significantly improve patient and practice outcomes. The Power of One Program is a contact lens strategy centered on 1-day and 1-month contact len
- WSJ: Roche Nears Deal to Buy Spark Therapeutics for Close to $5 Billionhttps://modernod.com/news/wsj-roche-nears-deal-to-buy-spark-therapeutics-for-close-to-5-billion/2476269/Swiss pharmaceutical company Roche is nearing a deal to buy Philadelphia-based biotechnology company Spark Therapeutics, according to a report in the Wall Street Journal
- Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with J&J’s Janssenhttps://modernod.com/news/morphic-therapeutic-enters-into-integrin-research-and-development-collaboration-with-jjs-janssen/2476272/Morphic Therapeutic announced that it has entered into a research and development collaboration with Johnson & Johnson’s subsidiary Janssen Biotech, to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. Johnson &a
- Allergan Responds to Public Shareholder Letterhttps://modernod.com/news/allergan-responds-to-public-shareholder-letter/2476274/Allergan issued the following statement from its Board of Directors in response to a public shareholder letter from Appaloosa hedge fund manager David Tepper earlier this week that stated the drugmaker should consider a merger or selling itself if it is “unable or unwilling to hold manageme
- Alcon Debuts iLux MGD Treatment System at SECOhttps://modernod.com/news/alcon-debuts-ilux-mgd-treatment-system-for-personalized-therapy-for-dry-eye-disease-at-seco/2476284/Alcon debuted the iLux MGD Treatment System at the SECO International 2019 annual meeting in New Orleans. The device, which received approval from the FDA in December 2017, helps eye care professionals provide comprehensive, in-office
- College of Optometrists in Vision Development & NORA Issue Joint Recommendation for Optometric Evaluation Following Brain Injuryhttps://modernod.com/news/college-of-optometrists-in-vision-development-nora-issue-joint-recommendation-for-optometric-evaluation-following-brain-injury/2476285/The College of Optometrists in Vision Development (COVD) and the Neuro Optometric Rehabilitation Association (NORA) issued a joint call-to-action to all healthcare professionals to consider the need for medical and/or functional optometric rehabilitation services for patients who have suffered a
- VSY Biotechnology and Carl Zeiss Meditec Settle Legal Disputeshttps://modernod.com/news/vsy-biotechnology-and-carl-zeiss-meditec-settle-legal-disputes/2476289/VSY Biotechnology BV and Carl Zeiss Meditec AG jointly announced that both companies resolved their legal and patent disputes with respect to the Tri-ED 611 IOL. The companies did not disclose the terms of the settlement.
- Leiters and Mobius Therapeutics Enter into National Sales and Marketing Agreement for Mitosolhttps://modernod.com/news/leiters-and-mobius-therapeutics-enter-into-national-sales-and-marketing-agreement-for-mitosol/2476290/Leiters and Mobius Therapeutics announced that they have entered into a national sales and marketing agreement for Mitosol, the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. Leiters, an FDA-registered 503B outsourcing provider
- Bausch + Lomb Receives 510(k) Clearance For Use Of The Tangible Hydra-PEG Custom Contact Lens Coatinghttps://modernod.com/news/bausch-lomb-receives-510k-clearance-for-use-of-the-tangible-hydra-peg-custom-contact-lens-coating-on-several-lenses/2476297/Bausch + Lomb announced it has received 510(k) clearance for use of the Tangible Hydra-PEG custom contact lens coating technology with some of its leading Boston gas permeable (GP) materials, the Boston XO, Boston XO2, Boston EO, and Boston ES lenses, including th